within Pharmacolibrary.Drugs.ATC.B;

model B01AC26
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.09,
    Cl             = 0.09116666666666666,
    adminDuration  = 600,
    adminMass      = 0.04,
    adminCount     = 1,
    Vd             = 0.424,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00038333333333333334,
    Tlag           = 7200
  );

  annotation(Documentation(
    info ="<html><body><p>Vorapaxar is an orally active, selective protease-activated receptor-1 (PAR-1) antagonist used as an antiplatelet agent to reduce thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. It is approved for clinical use in several regions including the United States and European Union.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects, both male and female, after oral administration of vorapaxar.</p><h4>References</h4><ol><li>Teddy Kosoglou, Bharath Kumar, Paul Statkevich, James E Schiller, Bhavna Kantesaria, Mary E Hanson, Christine McCrary Sisk, David L Cutler,Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.,Clinical pharmacology in drug development,2015<a href='https://pubmed.ncbi.nlm.nih.gov/27128003/'>https://pubmed.ncbi.nlm.nih.gov/27128003/</a></li><li>Jose-Angel Perez-Rivera, Jairo Monedero-Campo, Clara Cieza-Borrella, Pablo Ruiz-Perez,Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome.,Expert opinion on drug metabolism & toxicology,2017<a href='https://pubmed.ncbi.nlm.nih.gov/28135897/'>https://pubmed.ncbi.nlm.nih.gov/28135897/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AC26;
